Clinical Trial: Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial

U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07248696) titled 'Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial' on Nov. 18.

Brief Summary: This study is aimed to evaluate the efficacy and safety of tislelizumab combined with chemotherapy and response-adapted radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma

Study Start Date: Oct. 04

Study Type: INTERVENTIONAL

Condition: Nasopharyngeal Cancinoma (NPC)

Intervention: RADIATION: response-adapted radiotherapy

Induction Treatment Regimen:

* Tislelizumab+Gemcitabine+Cisplatin for 4-6 cycles .

Response-Adapted Radiotherapy:...